United States

Pliant Therapeutics is a clinical stage biopharmaceutical company that develops and commercializes therapies for fibrosis and related diseases. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. It is also developing two additional preclinical integrin-based programs, including an oncology program and a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies.

Google

Ürün Müdürü

Veri Bilimci

Pliant Therapeutics

Pliant Therapeutics Açık Pozisyonlar

Kariyerinizi bir üst seviyeye çıkarmaya hazır mısınız? Pliant Therapeutics'deki bu açık pozisyonlara göz atın.